Health technology assessment in Jordan: current landscape, challenges, and future roadmap

Read full text
Authors: Khawla Abu Hammour, Faris El‐Dahiyat, Zaheer-Ud-Din Babar, Fahmi Y. Al-Ashwal, Rana K. Abu-Farha
Cited by: 1
References: 21

Abstract

Background: Health Technology Assessment (HTA) is increasingly recognised as an essential tool for directing decisions on health policy, particularly those concerning coverage, reimbursement, price and value, especially in nations aiming for Universal Health Coverage (UHC). Jordan is a middle-income country with limited resources for the health sector and rising needs; thus, despite its significant progress toward institutionalising HTA, there are still many gaps. Objectives: To assess the present situation of HTA in Jordan, pinpoint the main facilitators and obstacles, and suggest a plan for enhancing HTA at Jordan University Hospital so that it can more methodically influence Jordanian health policy. Methods: Stakeholder studies, policy documents and published literature on HTA were reviewed, along with lessons learned from similar contexts. Results: Jordan's progress in HTA has been noteworthy. The Jordan Food and Drug Administration has specific requirements for pharmacoeconomic data in pricing and reimbursement, for instance, and university programs are providing capacity building. Other pioneers include the Ministry of Health, Royal Medical Services and the King Hussein Cancer Center's Centre for Drug Policy and Technology Assessment (KHCC CDPTA). However, funding for HTA is unstable, transparency and stakeholder engagement are uneven, institutional roles are fragmented, there is no national HTA methodological guideline or comprehensive, mandated legal framework, and data infrastructure (especially local cost, outcomes and real-world evidence) is limited. Conclusions: A strategic plan is required for all institutions to achieve the potential benefits of HTA in Jordan, including more equitable access, better prioritisation, more efficient spending and contributions to UHC. Formalising legal requirements, creating national methodological guidelines, enhancing institutional and human capacity, enhancing data systems, obtaining long-term funding, establishing precise decision criteria and thresholds and boosting transparency and stakeholder participation are important stages.

Fields of Study & Subjects

Health Systems Economic Evaluations Quality of Life Pharmaceutical Economics and Policy Healthcare Systems and Reforms

Publication details

Journal / source
Journal of Pharmaceutical Policy and Practice
Publisher
Informa UK Limited
Volume
19
Issue
1
Pages
2633823–2633823
Publication date
25 February 2026
Language
EN